Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
UksHMXRJhCZhWBUE
